Additionally, genetic variations reducing DNA-PK activity increase radiation-induced breast cancer susceptibility, and reluctance to PARP inhibitors in BRCA1-mutated tumour cells is mediated by DNA-PK activation, which enhances homologous recombination repair, contributing to chemotherapy resistance.216–218. This evidence concerns the gene PARP1 and breast carcinoma.